All Genzyme News

We have detected that your browser does not have Javascript turned on. This site is optimized for Javascript.
You may experience difficulties browsing certain parts of the site.

Genzyme UK Home

Genzyme Corporate Home

Genzyme Websites

Genzyme in the UK

Careers in the UK

News

	UK News
	All Genzyme News

All Genzyme News

Genzyme
December 9, 2009 Genzyme Laboratory Recognized for Quality
December 8, 2009 Robert J. Bertolini Elected to Genzyme’s Board of Directors
December 8, 2009 Genzyme’s Mozobil Shows Promise in Chemosensitization
December 7, 2009 Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL
December 3, 2009 Genzyme to Reopen Enrollment in Alglucosidase Alfa Temporary Access Program
December 1, 2009 Genzyme Begins Shipping Newly Produced Cerezyme from Allston Plant
November 18, 2009 Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder
November 17, 2009 Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHA
November 16, 2009 Genzyme Receives Complete Response Letter on Lumizyme Application
November 13, 2009 Genzyme Issues Letters to U.S. Healthcare Providers
October 21, 2009 Genzyme Reports Third-Quarter Financial Results
October 20, 2009 First Patient Enrolled in Phase 3 Trials of Genzyme Oral Capsule for Gaucher Disease
October 14, 2009 Scientists Name Genzyme a Top Employer
October 6, 2009 Genzyme Receives FDA Complete Response Letter for Clolar
October 2, 2009 Genzyme Named to Dow Jones Sustainability World and North American Indexes
September 24, 2009 Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia
September 23, 2009 Genzyme Provides Update on Cerezyme and Fabrazyme Supply
September 11, 2009 Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data
August 10, 2009 Genzyme Provides Update on Cerezyme Supply and 2009 Financial Information
July 22, 2009 Genzyme Delivers Solid Second-Quarter Financial Results
June 12, 2009 Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease
June 2, 2009 Genzyme Completes Transaction with Bayer HealthCare
March 2, 2009 Genzyme Receives Complete Response Letter from FDA on Lumizyme Application
February 26, 2009 European Authorities Approve Larger-Scale Production of Genzyme’s Myozyme
February 19, 2009 Genzyme Receives Positive Opinion on Myozyme from CHMP
October 15, 2008 Genzyme Begins Enrollment in Post-Marketing Study to Evaluate Use of Low Dose Fabrazyme Treatment for Fabry Disease
September 23, 2008 Mozobil Receives Priority Review with FDA Action Expected by Year End; Synvisc-ONE FDA Action also Expected by Year End


	CONTACT INFORMATION:
	Genzyme Therapeutics Ltd, Genzyme Biosurgery 4620 Kingsgate Cascade Way Oxford Business Park South Oxford OX4 2SU Tel: 01865 405200 Fax: 01865 774172 Genzyme Therapeutics Ltd Genzyme Europe Research 310 Cambridge Science Park Milton Road Cambridge CB4 0WG Tel: 01223 394000 Fax: 01223 394190 Genzyme Ltd Genzyme Diagnostics 50 Gibson Drive Kings Hill West Malling Kent ME19 4AF Tel: 01732 220022 Fax: 01732 220024 Genzyme Ltd Haverhill Operations 12 Rookwood Way Haverhill Suffolk CB9 8PU Tel: 01440 703522 Fax: 01440 716269 Registered Office for Genzyme Therapeutics Ltd 4620 Kingsgate Cascade Way Oxford Business Park South Oxford OX4 2SU Company Registration No. 4316333 Registered in England Registered Office for Genzyme Ltd 37 Hollands Road Haverhill Suffolk CB9 8PU Company Registration No. 01556886 Registered in England